Hematología y Hemoterapia

Resultados: 304
Tipo Título / Nombre Autor(es) Año
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, Bergua JM, et al 2021
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Álvarez RM..., Bermejo N, et al 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R, Vives S, Bergua JM, Torrent A, et al 2021
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, et al 2021
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q..., Bergua JM, et al 2021
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C..., Bergua JM, et al 2021
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, et al 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP, et al 2021
Leucemia aguda de fenotipo mixto (LAFM): descripción de características clínico-biológicas y análisis de supervivencia en cohorte de pacientes diagnosticados en Castilla y León (CYL) Avendaño Pita A, Yeguas Bermejo A, Cortés Rodríguez M, Pérez López E, Martin López A..., HIguero Saavedra V, et al 2020
A phase Ib, Open-Labe, Randomized Study to Asses Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab+ Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B cell –lymphoma: Analysis of the Safety Run in Phase Belada D, Nowakowski GS, Bergua Burgués JM, André M, Kopeckova K, Stevens DA, et al 2020